"Tuberculosis, Multidrug-Resistant" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.
- Tuberculosis, Multidrug-Resistant
- Multidrug-Resistant Tuberculosis
- Tuberculosis, Multidrug Resistant
- Tuberculosis, MDR
- MDR Tuberculosis
- Tuberculosis, Multi-Drug Resistant
- Multi-Drug Resistant Tuberculosis
- Tuberculosis, Multi Drug Resistant
Below are MeSH descriptors whose meaning is more general than "Tuberculosis, Multidrug-Resistant".
Below are MeSH descriptors whose meaning is more specific than "Tuberculosis, Multidrug-Resistant".
This graph shows the total number of publications written about "Tuberculosis, Multidrug-Resistant" by people in Harvard Catalyst Profiles by year, and whether "Tuberculosis, Multidrug-Resistant" was a major or minor topic of these publication.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
Below are the most recent publications written about "Tuberculosis, Multidrug-Resistant" by people in Profiles.
Decentralized, Integrated Treatment of RR/MDR-TB and HIV Using a Bedaquiline-Based, Short-Course Regimen Is Effective and Associated With Improved HIV Disease Control. J Acquir Immune Defic Syndr. 2023 Apr 15; 92(5):385-392.
Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB. Int J Tuberc Lung Dis. 2023 Jan 01; 27(1):34-40.
Low Body Mass Index at Treatment Initiation and Rifampicin-Resistant Tuberculosis Treatment Outcomes: An Individual Participant Data Meta-Analysis. Clin Infect Dis. 2022 12 19; 75(12):2201-2210.
Tuberculosis treatment failure associated with evolution of antibiotic resilience. Science. 2022 12 09; 378(6624):1111-1118.
A very sneaky bug: perspectives of front-line clinicians on whole-genome sequencing for drug-resistant TB. Int J Tuberc Lung Dis. 2022 12 01; 26(12):1180-1182.
Selection bias in multidrug-resistant tuberculosis cohort studies assessing sputum culture conversion. PLoS One. 2022; 17(11):e0276457.
Celebrating choice in the care of people living with drug-resistant tuberculosis. Lancet. 2022 10 29; 400(10362):1489-1491.
Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs. Clin Infect Dis. 2022 10 12; 75(8):1307-1314.
Pediatric delamanid treatment for children with rifampicin-resistant TB. Int J Tuberc Lung Dis. 2022 10 01; 26(10):986-988.
Budget impact of next-generation sequencing for diagnosis of TB drug resistance in Moldova. Int J Tuberc Lung Dis. 2022 10 01; 26(10):963-969.